FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers
Valeura Energy: Positioned for Organic Growth and Accretive M&A in Southeast Asia’s Offshore Oil Sector
